Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Change in Account Payables (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Change in Account Payables data on record, last reported at -$866000.0 in Q4 2021.

  • For Q4 2021, Change in Account Payables fell 1031.18% year-over-year to -$866000.0; the TTM value through Dec 2021 reached $2.8 million, up 212.24%, while the annual FY2025 figure was -$2.5 million, 284.76% down from the prior year.
  • Change in Account Payables reached -$866000.0 in Q4 2021 per COGT's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.4 million in Q3 2021 and bottomed at -$2.6 million in Q1 2020.
  • Average Change in Account Payables over 4 years is $145687.5, with a median of $5500.0 recorded in 2020.
  • The widest YoY moves for Change in Account Payables: up 41825.0% in 2021, down 1031.18% in 2021.
  • A 4-year view of Change in Account Payables shows it stood at $716000.0 in 2018, then surged by 121.93% to $1.6 million in 2019, then tumbled by 94.15% to $93000.0 in 2020, then tumbled by 1031.18% to -$866000.0 in 2021.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$866000.0 in Q4 2021, $2.4 million in Q3 2021, and $1.7 million in Q2 2021.